Literature DB >> 21917081

CpG island methylation of microRNAs is associated with tumor size and recurrence of non-small-cell lung cancer.

Kentaro Kitano1, Kousuke Watanabe, Noriko Emoto, Hidenori Kage, Emi Hamano, Takahide Nagase, Atsushi Sano, Tomohiro Murakawa, Jun Nakajima, Akiteru Goto, Masashi Fukayama, Yutaka Yatomi, Nobuya Ohishi, Daiya Takai.   

Abstract

We investigated whether the CpG island methylation of certain microRNAs was associated with the clinicopathological features and the prognosis of non-small-cell lung cancer. The methylation of mir-152, -9-3, -124-1, -124-2, and -124-3 was analyzed in 96 non-small-cell lung cancer specimens using a combined bisulfite restriction analysis. The median observation period was 49.5 months. The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independent of age, sex, and smoking habit. Moreover, the methylation of multiple microRNA loci was associated with a poorer progression-free survival in a univariate analysis. Our result enlightens the accumulation of aberrant DNA methylation which occurs in concordance with the tumor progression.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917081     DOI: 10.1111/j.1349-7006.2011.02101.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  19 in total

1.  Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.

Authors:  Hyang Sook Seol; Yoshimitsu Akiyama; Shu Shimada; Hee Jin Lee; Tae Im Kim; Sung Min Chun; Shree Ram Singh; Se Jin Jang
Journal:  Cancer Lett       Date:  2014-07-22       Impact factor: 8.679

2.  MicroRNAs As Biomarkers For Clinical Features Of Lung Cancer.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey S S Enfield; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Metabolomics (Los Angel)       Date:  2012-03-21

Review 3.  Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer.

Authors:  Reo Maruyama; Hiromu Suzuki; Eiichiro Yamamoto; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2012-01-05

4.  A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer.

Authors:  Yuji Toiyama; Yoshinaga Okugawa; Koji Tanaka; Toshimitsu Araki; Keiichi Uchida; Asahi Hishida; Motoi Uchino; Hiroki Ikeuchi; Seiichi Hirota; Masato Kusunoki; C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2017-08-25       Impact factor: 22.682

5.  Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells.

Authors:  Linbo Gao; David Cheng; Jie Yang; Renyi Wu; Wenji Li; Ah-Ng Kong
Journal:  J Nutr Biochem       Date:  2018-02-09       Impact factor: 6.048

6.  DNA methylation in cord blood as mediator of the association between prenatal arsenic exposure and gestational age.

Authors:  Anne K Bozack; Andres Cardenas; Quazi Quamruzzaman; Mahmuder Rahman; Golam Mostofa; David C Christiani; Molly L Kile
Journal:  Epigenetics       Date:  2018-10-11       Impact factor: 4.528

7.  A suite of DNA methylation markers that can detect most common human cancers.

Authors:  Lukas Vrba; Bernard W Futscher
Journal:  Epigenetics       Date:  2018-02-19       Impact factor: 4.528

8.  MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Authors:  Jon S Zawistowski; Kazuhiro Nakamura; Joel S Parker; Deborah A Granger; Brian T Golitz; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

Review 9.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

10.  Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer.

Authors:  Hengli Dou; Yan Wang; Gang Su; Song Zhao
Journal:  Int J Clin Exp Med       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.